X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PLETHICO PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PLETHICO PHARMA DISHMAN PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 25.1 -1.1 - View Chart
P/BV x 3.3 0.0 19,969.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PLETHICO PHARMA
Mar-14
DISHMAN PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs374395 94.8%   
Low Rs12931 411.8%   
Sales per share (Unadj.) Rs197.8604.4 32.7%  
Earnings per share (Unadj.) Rs21.232.5 65.3%  
Cash flow per share (Unadj.) Rs34.751.3 67.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9473.6 38.0%  
Shares outstanding (eoy) m80.6934.08 236.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.4 360.8%   
Avg P/E ratio x11.96.6 180.9%  
P/CF ratio (eoy) x7.24.2 174.6%  
Price / Book Value ratio x1.40.5 310.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,262 279.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3551,596 335.5%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96120,598 77.5%  
Other income Rs m265386 68.7%   
Total revenues Rs m16,22620,984 77.3%   
Gross profit Rs m4,1032,818 145.6%  
Depreciation Rs m1,091642 169.8%   
Interest Rs m9441,593 59.3%   
Profit before tax Rs m2,334969 240.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-138 -450.6%   
Profit after tax Rs m1,7111,107 154.6%  
Gross profit margin %25.713.7 187.9%  
Effective tax rate %26.7-14.3 -187.0%   
Net profit margin %10.75.4 199.5%  
BALANCE SHEET DATA
Current assets Rs m11,01818,877 58.4%   
Current liabilities Rs m9,51711,896 80.0%   
Net working cap to sales %9.433.9 27.7%  
Current ratio x1.21.6 73.0%  
Inventory Days Days11036 307.5%  
Debtors Days Days35198 17.6%  
Net fixed assets Rs m16,3049,861 165.3%   
Share capital Rs m161341 47.4%   
"Free" reserves Rs m12,90712,331 104.7%   
Net worth Rs m14,51616,139 89.9%   
Long term debt Rs m4,1894,706 89.0%   
Total assets Rs m29,80533,146 89.9%  
Interest coverage x3.51.6 215.9%   
Debt to equity ratio x0.30.3 99.0%  
Sales to assets ratio x0.50.6 86.2%   
Return on assets %8.98.1 109.4%  
Return on equity %11.86.9 171.9%  
Return on capital %17.512.3 142.6%  
Exports to sales %24.821.4 116.0%   
Imports to sales %3.715.2 24.5%   
Exports (fob) Rs m3,9564,402 89.9%   
Imports (cif) Rs m5963,136 19.0%   
Fx inflow Rs m4,9524,402 112.5%   
Fx outflow Rs m6973,184 21.9%   
Net fx Rs m4,2551,219 349.2%   
CASH FLOW
From Operations Rs m2,7862,437 114.3%  
From Investments Rs m-1,529-6,265 24.4%  
From Financial Activity Rs m-9412,490 -37.8%  
Net Cashflow Rs m316-1,337 -23.7%  

Share Holding

Indian Promoters % 61.4 82.7 74.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.3 86.0%  
FIIs % 12.7 5.5 230.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 7.5 294.7%  
Shareholders   46,261 10,665 433.8%  
Pledged promoter(s) holding % 35.8 85.7 41.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS